- Chemical class: C10H18O tertiary alcohol monoterpenoid — the oxygen atom distinguishes it from pure hydrocarbon terpenes like limonene and myrcene.
- GABA-A modulation: Linck (2010) confirmed inhaled linalool produces benzodiazepine-like sedation via GABA-A positive allosteric modulation — without direct benzodiazepine binding site activation, meaning lower dependence potential.
- Serotonergic: 5-HT1A partial agonism (Pereira 2018 review) contributes mood-regulating anxiolytic activity complementary to the GABAergic pathway.
- Anti-nociceptive: NMDA antagonism and spinal cord glutamate reduction (Peana 2003, 2004); voltage-gated sodium channel blockade for local anesthetic effect (Ghelardini 1999).
- Wound healing: Mori (2016) demonstrated epidermal regeneration and keratinocyte migration acceleration in linalool-treated wound models.
- Alzheimer’s model: Pereira (2018) found linalool acetate reduces tau phosphorylation — the hallmark pathological process of Alzheimer’s disease — in cell models.
- Pharmaceutical validation: Silexan (oral lavender oil, predominantly linalool) approved in Germany; comparable efficacy to lorazepam in head-to-head RCT without addiction or cognitive side effects.
What Is Linalool?
Linalool is a naturally occurring tertiary terpene alcohol (monoterpenoid) with molecular formula C10H18O and molecular weight 154.25 g/mol. It is found in over 200 plant species across numerous botanical families and is particularly concentrated in lavender (Lavandula angustifolia), where it constitutes 25–45% of the essential oil by weight. Unlike purely hydrocarbon monoterpenes such as limonene or myrcene, linalool carries a hydroxyl (-OH) group, making it a terpene alcohol with distinct polarity and solubility characteristics that influence its pharmacokinetics.
Linalool exists as two enantiomers: (R)-linalool (licareol, more common in coriander and some herbs) and (S)-linalool (coriandrol, dominant in lavender and cannabis). The (S)-form is primarily responsible for the documented pharmacological effects, including GABA-A modulation and 5-HT1A activity. Cannabis produces predominantly (S)-linalool, consistent with the sedating, calming character associated with high-linalool cultivars.
The cultural tradition of lavender for relaxation, sleep support, and anxiety relief — practiced across ancient Rome, Egypt, and Arabia, and documented continuously in European herbalism for over two millennia — is now understood to be substantially mediated by linalool’s direct pharmacological activity at GABA-A receptors. This centuries-old empirical observation has been rigorously validated in modern clinical trials, most notably those supporting the regulatory approval of Silexan as an anxiolytic pharmaceutical in Germany and across Europe. Linalool stands as perhaps the most pharmaceutically validated terpene in cannabis, bridging traditional plant medicine and contemporary neuropharmacology.
Chemical Properties
| Property | Detail |
|---|---|
| IUPAC Name | (S)-3,7-dimethylocta-1,6-dien-3-ol [(S)-linalool] |
| Molecular Formula | C10H18O |
| Molecular Weight | 154.25 g/mol |
| Boiling Point | 198°C (388°F) at 1 atm |
| Aroma | Floral, lavender, spicy, slightly woody |
| Solubility | Slightly water-soluble (5 g/L); lipophilic; miscible with ethanol |
| Cannabis concentration range | 0.01–0.5% of total flower weight |
| Active enantiomer in cannabis | (S)-linalool predominantly |
| Lavender EO content | 25–45% of total lavender essential oil |
| FDA status | GRAS as food and fragrance ingredient |
Biosynthesis: MEP Pathway and Linalool Synthase
Like other monoterpenes in cannabis, linalool is synthesized via the methylerythritol phosphate (MEP) pathway in plastids. The precursor geranyl pyrophosphate (GPP) undergoes cyclization and rearrangement by linalool synthase — a specific terpene synthase enzyme — to produce the acyclic tertiary alcohol structure. The linalool synthase gene family in cannabis shows variable expression across chemovars, which accounts for the wide range of linalool concentrations observed in different cultivars.
Unlike sesquiterpenes (C15), which are produced via the mevalonate (MVA) pathway in the cytosol, monoterpene linalool is produced predominantly in plastids and accumulates in trichome secretory cells. UV-B radiation, temperature, and soil composition all modulate terpene synthase expression during plant development. Late-stage maturation of trichome heads is associated with peak linalool accumulation, making harvest timing critical for preserving linalool-rich profiles in cannabis production.
A significant portion of linalool in plants exists as linalool acetate (formed by acetylation of the hydroxyl group), which is also pharmacologically active and contributes to the characteristic lavender aroma. In cannabis, both linalool and linalool acetate are detectable in terpene analyses, with the free alcohol form typically predominating.
Mechanism of Action: Receptor Targets
GABA-A Positive Allosteric Modulation: The primary mechanism behind linalool’s anxiolytic and sedative effects is positive allosteric modulation of GABA-A receptors. These ligand-gated chloride channels are the primary targets of benzodiazepines (diazepam, alprazolam) and barbiturates. Linalool enhances GABA-A receptor function by binding to an allosteric site distinct from the benzodiazepine binding site, increasing the frequency of chloride channel opening in response to GABA. This mechanism increases overall GABAergic tone — the brain’s primary inhibitory neurotransmitter system — producing measurable anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects at therapeutic concentrations without the full agonism that characterizes addictive benzodiazepines.
5-HT1A Serotonin Receptor Partial Agonism: Linalool also engages the serotonin 1A receptor as a partial agonist, contributing mood-stabilizing and additional anxiolytic activity through the serotonin system. This dual-pathway mechanism — GABAergic inhibition plus serotonergic modulation — is pharmacologically analogous to the way buspirone (an anxiolytic drug) operates, and it helps explain why linalool’s anxiolytic effect is notably well-tolerated compared to pure GABAergic agents.
NMDA Receptor Antagonism: Linalool inhibits NMDA (N-methyl-D-aspartate) glutamate receptors, reducing excitatory neurotransmission. This mechanism contributes to both anticonvulsant effects (by reducing seizure-threshold-lowering glutamate activity) and analgesic effects (by blocking pain signal amplification in the spinal cord). Peana and colleagues (2003, 2004) specifically demonstrated this spinal cord glutamate inhibition pathway in analgesic studies.
Voltage-Gated Sodium Channel Blockade: Ghelardini and colleagues (1999) demonstrated that linalool blocks voltage-gated sodium channels — the same mechanism used by local anesthetics like lidocaine and novocaine. This channel blockade reduces pain signal propagation from the site of injury to the central nervous system, providing a topical analgesic mechanism relevant to cannabis topical products.
Medical Evidence Table
| Study / Author | Model | Dose / Exposure | Outcome | Evidence Level |
|---|---|---|---|---|
| Linck et al. (2010) | Rodent, inhalation | Inhaled linalool vapor | Benzodiazepine-like anxiolytic and sedative effects; GABA-A mechanism | Strong (animal) |
| Silexan RCTs (multiple, 2010–2016) | GAD patients, double-blind RCT | 80 mg/day oral (Silexan, linalool-standardized lavender oil) | Significant HAM-A reduction; comparable to lorazepam 0.5 mg/day | Strong (clinical RCT) |
| Elisabetsky et al. (1995) | Rodent seizure models | i.p. linalool | Anticonvulsant effect; glutamate inhibition mechanism | Moderate (animal) |
| Peana et al. (2003, 2004) | Rodent pain models | i.p. linalool | Dose-dependent analgesia; NMDA antagonism, spinal cord glutamate reduction | Moderate (animal) |
| Ghelardini et al. (1999) | Rodent local anesthesia model | Topical linalool | Significant local anesthetic effect; voltage-gated Na+ channel blockade | Moderate (animal) |
| Mori et al. (2016) | In vitro wound healing model | Linalool treatment of keratinocytes | Enhanced epidermal regeneration; keratinocyte migration acceleration | Moderate (in vitro) |
| Pereira et al. (2018) | Alzheimer’s cell model | Linalool acetate treatment | Reduced tau phosphorylation; neuroprotective potential in AD model | Preliminary (in vitro) |
| Pereira et al. (2018 review) | Literature review | Multiple studies | Confirmed 5-HT1A partial agonism; comprehensive CNS mechanism overview | Moderate (review) |
Top Cannabis Strains Highest in Linalool
High-linalool strains are associated with calming, sleep-supportive, and anxiety-reducing effects. The following cultivars consistently place linalool at meaningful levels in their terpene profiles and are among the most widely recognized for their distinctive floral, calming character.
| Strain | Type | Linalool % | Co-Terpenes | Primary Effect |
|---|---|---|---|---|
| Lavender (Lavender Kush) | Indica | 0.20–0.50% | Myrcene, caryophyllene | Deep relaxation, sleep, anxiety relief |
| Do-Si-Dos | Indica-dominant Hybrid | 0.15–0.40% | Limonene, caryophyllene | Calming, euphoric, sedating |
| Zkittlez | Indica-dominant Hybrid | 0.10–0.30% | Myrcene, humulene | Calm, happy, relaxed |
| Kosher Kush | Indica | 0.15–0.38% | Myrcene, caryophyllene | Heavily sedating, pain relief |
| Amnesia Haze | Sativa-dominant Hybrid | 0.10–0.30% | Terpinolene, myrcene | Uplifted calm, creative |
| LA Confidential | Indica | 0.15–0.35% | Myrcene, pinene | Sedating, pain relief, sleep |
| OG Shark | Indica-dominant Hybrid | 0.12–0.28% | Myrcene, limonene | Relaxation, stress relief |
| Purple Urkle | Indica | 0.12–0.30% | Myrcene, caryophyllene | Deeply relaxing, sleepy, euphoric |
Entourage Effect Synergies
| Partner Compound | Interaction Type | Clinical Relevance |
|---|---|---|
| CBD | Additive 5-HT1A agonism + anti-inflammatory | Enhanced anxiolytic; high-CBD, high-linalool formulations studied for anxiety and sleep disorders |
| THC | Modulatory (linalool counteracts THC anxiety) | GABA-A tone increase may buffer CB1-mediated anxiety; indica strains with both benefit |
| Myrcene | Additive sedation (GABAergic + BBB permeability) | Powerful sleep-support stack; LA Confidential, Lavender Kush exemplify this combination |
| Limonene | Complementary (serotonin + GABA dual pathway) | Broader anti-anxiety coverage; Do-Si-Dos contains both at meaningful levels |
| Caryophyllene | Additive (GABA-A + CB2 anti-inflammatory) | Enhanced pain-anxiety synergy; common in OG Kush lineage strains |
Non-Cannabis Natural Sources
| Source | Linalool Content | Traditional / Commercial Use |
|---|---|---|
| Lavender (Lavandula angustifolia) | 25–45% of essential oil | Aromatherapy, Silexan pharmaceutical, fragrance, cosmetics |
| Coriander seed (Coriandrum sativum) | 60–80% of essential oil | Food flavoring, fragrance, traditional medicine |
| Sweet basil (Ocimum basilicum) | Up to 30% of essential oil | Culinary herb, fragrance |
| Rosewood (Aniba rosaeodora) | 80–95% of essential oil | High-end perfumery; endangered species, largely replaced by synthetic linalool |
| Bergamot (Citrus bergamia) | Up to 15% of essential oil | Earl Grey tea, fragrance, aromatherapy |
| Ho wood (Cinnamomum camphora) | 80–90% of essential oil | Primary commercial source of linalool for flavor and fragrance industry |
Extraction and Commercial Applications
Linalool is among the most commercially produced terpene alcohols in the world. The primary industrial sources are ho wood (Cinnamomum camphora linaloolifera), coriander seed, and rosewood, though sustainability concerns have driven much of the fragrance industry toward synthetic linalool produced from petrochemical alpha-pinene via semi-synthesis.
In the fragrance industry, linalool is ubiquitous — it appears in an estimated 60–80% of scented consumer products, including soaps, shampoos, detergents, perfumes, and cosmetics, where it contributes floral, clean, and calming notes. This pervasive use has made it one of the most common fragrance allergens documented in dermatological studies, primarily because oxidized linalool (linalool hydroperoxides) is sensitizing. Fresh, unexposed linalool is considerably less allergenic.
In pharmaceutical contexts, linalool is the primary active component of Silexan (WS®1265), a standardized lavender oil preparation. The commercial development of Silexan represents the most successful translation of a cannabis-adjacent terpene into a registered pharmaceutical product, providing both a validation of linalool’s therapeutic properties and a template for future terpene drug development.
In cannabis processing, linalool is preserved in cold-process ethanol extraction and supercritical CO2 extraction at low temperatures. Its higher boiling point (198°C) relative to lighter terpenes means it survives better in extraction processes, but it remains sensitive to oxidation and prolonged heat exposure. Live resin and fresh-frozen extraction methods preserve the highest linalool fractions from fresh cannabis biomass.
Safety and Toxicology
Linalool has a well-established safety profile. FDA classifies it as GRAS for food and fragrance use. EFSA has reviewed linalool as a food flavoring and found no safety concerns at typical dietary exposure levels. In the context of cannabis, the concentrations of linalool encountered in normal flower consumption are orders of magnitude below any identified adverse effect threshold.
The primary safety consideration for linalool is its sensitization potential when oxidized. Linalool exposed to air forms linalool hydroperoxides, which are skin sensitizers at fragrance industry concentrations. For cannabis products, this means freshness and proper storage (dark, sealed, cool) preserve both therapeutic value and minimize oxidation product formation. Contact dermatitis from linalool-containing cannabis topicals is theoretically possible but rarely documented in clinical literature.
Oral LD50 in rats is approximately 2.79 g/kg, well above any realistic consumption level. No reproductive toxicity, genotoxicity, or carcinogenicity has been identified at relevant doses. Clinical Silexan trials at 80 mg/day (equivalent to substantial daily linalool intake) confirmed excellent tolerability over extended treatment periods.
Frequently Asked Questions
What does linalool smell like in cannabis?
Linalool produces a floral, lavender-dominant aroma with subtle spicy and woody undertones. In cannabis strains with significant linalool content, the scent is noticeably softer and more perfumed — less dank or citrusy, more reminiscent of a lavender field. Strains like Lavender Kush and Do-Si-Dos are classic examples where linalool creates an unmistakably calming aromatic character. The floral quality often softens stronger terpenes like myrcene or caryophyllene in the same profile.
How does linalool reduce anxiety?
Linalool reduces anxiety primarily through positive allosteric modulation of GABA-A receptors — the same receptor complex targeted by benzodiazepines. Linck and colleagues (2010) confirmed this mechanism in controlled animal studies. Additionally, linalool shows 5-HT1A serotonin receptor partial agonism (Pereira 2018), adding a mood-regulating component. The combination of GABAergic and serotonergic mechanisms produces well-tolerated, broad-spectrum anxiety reduction without the addiction potential of pharmaceutical benzodiazepines.
Is there approved medicine made from linalool?
Yes. Silexan is an oral lavender oil preparation standardized to high linalool content, approved in Germany for generalized anxiety disorder. Randomized controlled trials demonstrated Silexan at 80 mg/day produced significant reductions in Hamilton Anxiety Rating Scale scores. A head-to-head comparison found it comparable in efficacy to lorazepam 0.5 mg/day without the addiction risk, sedation, or cognitive impairment associated with benzodiazepines. This is the strongest clinical evidence base for any cannabis terpene in pharmaceutical use.
Does linalool help with pain?
Yes. Peana and colleagues (2003, 2004) demonstrated dose-dependent analgesic activity via NMDA antagonism and spinal cord glutamate reduction. Ghelardini (1999) showed voltage-gated sodium channel blockade producing local anesthetic effects. COX inhibition adds an anti-inflammatory analgesic layer. These overlapping pain pathways make linalool-rich strains particularly well-suited for patients managing pain conditions that co-present with anxiety or insomnia, where the combined anxiolytic and analgesic profile addresses both dimensions simultaneously.